Covered recipient · General Payments record
ANUJ BHARGAVA
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$15,809.66
67 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $14,189.58 | 36 |
| Food and Beverage | $1,466.59 | 30 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $153.49 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Eli Lilly and Company | $13,789.17 | 45 |
| Boehringer Ingelheim International GmbH | $1,348.85 | 11 |
| Medtronic, Inc. | $182.50 | 2 |
| MannKind Corporation | $168.67 | 2 |
| Ascensia Diabetes Care Us Inc. | $120.12 | 1 |
| Dexcom, Inc. | $85.07 | 4 |
| Novo Nordisk Inc | $72.93 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $42.35 | 1 |
Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ANUJ BHARGAVA
NPI 1669563052 · CMS profile ID 211123
Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism
DES MOINES, IA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1669563052?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ANUJ BHARGAVA, NPI 1669563052, CMS profile ID 211123. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669563052?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). ANUJ BHARGAVA, NPI 1669563052, CMS profile ID 211123. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669563052?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- ANUJ BHARGAVA, NPI 1669563052, CMS profile ID 211123, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1669563052?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
67 matching records · $15,809.66 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–67 of 67.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Eli Lilly and Company | $24.97 | 03/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031267949 | CMS |
| Eli Lilly and Company | $13.93 | 03/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031268471 | CMS |
| Eli Lilly and Company | $3.98 | 03/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031268473 | CMS |
| Eli Lilly and Company | $199.00 | 03/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031268475 | CMS |
| Eli Lilly and Company | $13.93 | 03/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031268477 | CMS |
| Eli Lilly and Company | $3.98 | 03/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031268479 | CMS |
| Eli Lilly and Company | $3.98 | 03/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031268481 | CMS |
| Eli Lilly and Company | $59.98 | 03/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031268483 | CMS |
| Eli Lilly and Company | $24.99 | 03/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031268485 | CMS |
| Eli Lilly and Company | $200.60 | 03/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031268487 | CMS |
| Eli Lilly and Company | $257.30 | 03/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031275923 | CMS |
| Eli Lilly and Company | $13.93 | 03/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031275925 | CMS |
| Eli Lilly and Company | $1,926.00 | 03/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031275927 | CMS |
| Eli Lilly and Company | $199.00 | 03/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031275929 | CMS |
| Eli Lilly and Company | $475.00 | 03/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031275931 | CMS |
| MannKind Corporation | $153.49 | 02/02/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056255109 | CMS |
| Dexcom, Inc. | $17.32 | 01/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1054705661 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,958,231.43 | 423 |
| PY2024 | Recipient | $86,155.00 | 6 |
| PY2024 | Principal investigator | $4,215,716.41 | 321 |
| PY2023 | Recipient | $2,137.99 | 7 |
| PY2023 | Principal investigator | $4,357,402.29 | 417 |
| PY2022 | Recipient | $96,905.00 | 9 |
| PY2022 | Principal investigator | $2,511,709.23 | 468 |
| PY2021 | Recipient | $604.94 | 3 |
| PY2021 | Principal investigator | $2,539,988.96 | 858 |
| PY2020 | Recipient | $13,104.90 | 6 |
| PY2020 | Principal investigator | $2,465,406.24 | 551 |
| PY2019 | Recipient | $12,147.83 | 5 |
| PY2019 | Principal investigator | $2,249,315.63 | 274 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
423 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $5,520.00 | 12/31/2025 | Non-covered Recipient Entity MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY | A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism | No dispute reported | 06/30/2026 | 1202534581 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754853 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754859 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754865 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754872 |
| Principal investigator 1 | Sequel Med Tech, LLC | $3,200.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754877 |
| Principal investigator 1 | Sequel Med Tech, LLC | $1,120.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754884 |
| Principal investigator 1 | Sequel Med Tech, LLC | $8,000.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754889 |
| Principal investigator 1 | Sequel Med Tech, LLC | $2,800.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754895 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754901 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754907 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754914 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754920 |
| Principal investigator 1 | Sequel Med Tech, LLC | $3,200.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754926 |
| Principal investigator 1 | Sequel Med Tech, LLC | $1,120.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754932 |
| Principal investigator 1 | Sequel Med Tech, LLC | $2,223.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754938 |
| Principal investigator 1 | Sequel Med Tech, LLC | $778.05 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754944 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754950 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754955 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754961 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754967 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754973 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754977 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754983 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754989 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754995 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243755000 |
| Principal investigator 1 | Sequel Med Tech, LLC | $3,200.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243755004 |
| Principal investigator 1 | Sequel Med Tech, LLC | $1,120.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243755008 |
| Principal investigator 1 | Sequel Med Tech, LLC | $3,200.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243755013 |
| Principal investigator 1 | Sequel Med Tech, LLC | $1,120.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243755019 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243755027 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243755033 |
| Principal investigator 1 | Sequel Med Tech, LLC | $3,200.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243755039 |
| Principal investigator 1 | Sequel Med Tech, LLC | $1,120.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243755045 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243755051 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243755057 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243755063 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243755069 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243755073 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243755078 |
| Principal investigator 1 | Sequel Med Tech, LLC | $2,223.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243755084 |
| Principal investigator 1 | Sequel Med Tech, LLC | $778.05 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243755090 |
| Principal investigator 1 | Sequel Med Tech, LLC | $3,200.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243755096 |
| Principal investigator 1 | Sequel Med Tech, LLC | $1,120.00 | 12/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243755102 |
| Principal investigator 1 | Abbott Laboratories | $248.00 | 12/22/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136854 |
| Principal investigator 1 | Abbott Laboratories | $72.00 | 12/22/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136856 |
| Principal investigator 1 | Abbott Laboratories | $74.00 | 12/22/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136858 |
| Principal investigator 1 | Abbott Laboratories | $74.00 | 12/22/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136860 |
| Principal investigator 1 | Abbott Laboratories | $19.00 | 12/22/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136862 |
| Principal investigator 1 | Abbott Laboratories | $248.00 | 12/22/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136864 |
| Principal investigator 1 | Abbott Laboratories | $1.55 | 12/22/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136866 |
| Principal investigator 1 | Abbott Laboratories | $17.40 | 12/22/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136868 |
| Principal investigator 1 | Abbott Laboratories | $610.00 | 12/22/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136870 |
| Principal investigator 1 | Novo Nordisk AS | $395.44 | 12/22/2025 | Non-covered Recipient Entity MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY | NN9535-4352 | No dispute reported | 06/30/2026 | 1213706246 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,268.80 | 12/09/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220791184 |
| Principal investigator 1 | Sequel Med Tech, LLC | $47.25 | 12/05/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243754371 |
| Principal investigator 1 | Abbott Laboratories | $186.00 | 12/04/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136852 |
| Principal investigator 1 | Abbott Laboratories | $122.00 | 12/03/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136848 |
| Principal investigator 1 | Abbott Laboratories | $248.00 | 12/03/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136850 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619820 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619822 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619824 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619826 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619828 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619830 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751648 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751653 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751659 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751665 |
| Principal investigator 1 | Sequel Med Tech, LLC | $2,223.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751669 |
| Principal investigator 1 | Sequel Med Tech, LLC | $778.05 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751674 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751680 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751686 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751691 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751700 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751706 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751710 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751716 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751723 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751729 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751736 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751741 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751748 |
| Principal investigator 1 | Sequel Med Tech, LLC | $2,223.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751756 |
| Principal investigator 1 | Sequel Med Tech, LLC | $778.05 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751762 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751768 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751774 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751780 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751786 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751790 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751796 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751802 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751807 |
| Principal investigator 1 | Sequel Med Tech, LLC | $2,223.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751815 |
| Principal investigator 1 | Sequel Med Tech, LLC | $778.05 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751820 |
| Principal investigator 1 | Sequel Med Tech, LLC | $3,200.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751828 |
| Principal investigator 1 | Sequel Med Tech, LLC | $1,120.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751834 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751838 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751843 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751848 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751854 |
| Principal investigator 1 | Sequel Med Tech, LLC | $3,200.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751859 |
| Principal investigator 1 | Sequel Med Tech, LLC | $1,120.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751863 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751868 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751875 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751880 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751885 |
| Principal investigator 1 | Sequel Med Tech, LLC | $3,200.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751890 |
| Principal investigator 1 | Sequel Med Tech, LLC | $1,120.00 | 11/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243751896 |
| Principal investigator 1 | Abbott Laboratories | $6,166.32 | 11/26/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248160316 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $391.52 | 11/26/2025 | Non-covered Recipient Entity Iowa Diabetes | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220814605 |
| Principal investigator 1 | Abbott Laboratories | $7,500.00 | 11/17/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248160250 |
| Principal investigator 1 | Abbott Laboratories | $122.00 | 11/14/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136832 |
| Principal investigator 1 | Abbott Laboratories | $72.00 | 11/14/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136834 |
| Principal investigator 1 | Abbott Laboratories | $74.00 | 11/14/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136836 |
| Principal investigator 1 | Abbott Laboratories | $74.00 | 11/14/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136838 |
| Principal investigator 1 | Abbott Laboratories | $248.00 | 11/14/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136840 |
| Principal investigator 1 | Abbott Laboratories | $19.00 | 11/14/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136842 |
| Principal investigator 1 | Abbott Laboratories | $17.70 | 11/14/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136844 |
| Principal investigator 1 | Abbott Laboratories | $79.00 | 11/14/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136846 |
| Principal investigator 1 | ABBVIE INC. | $17,598.96 | 11/05/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202523063 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619808 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619810 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619812 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619814 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619816 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619818 |
| Principal investigator 1 | Sequel Med Tech, LLC | $3,200.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748662 |
| Principal investigator 1 | Sequel Med Tech, LLC | $1,120.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748669 |
| Principal investigator 1 | Sequel Med Tech, LLC | $2,223.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748675 |
| Principal investigator 1 | Sequel Med Tech, LLC | $778.05 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748680 |
| Principal investigator 1 | Sequel Med Tech, LLC | $3,200.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748684 |
| Principal investigator 1 | Sequel Med Tech, LLC | $1,120.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748690 |
| Principal investigator 1 | Sequel Med Tech, LLC | $2,223.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748695 |
| Principal investigator 1 | Sequel Med Tech, LLC | $778.05 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748702 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748707 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748713 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748718 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748724 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748730 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748736 |
| Principal investigator 1 | Sequel Med Tech, LLC | $2,223.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748743 |
| Principal investigator 1 | Sequel Med Tech, LLC | $778.05 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748748 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748754 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748761 |
| Principal investigator 1 | Sequel Med Tech, LLC | $2,223.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748767 |
| Principal investigator 1 | Sequel Med Tech, LLC | $778.05 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748774 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748781 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748786 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748792 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748798 |
| Principal investigator 1 | Sequel Med Tech, LLC | $2,223.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748803 |
| Principal investigator 1 | Sequel Med Tech, LLC | $778.05 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748810 |
| Principal investigator 1 | Sequel Med Tech, LLC | $3,200.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748816 |
| Principal investigator 1 | Sequel Med Tech, LLC | $1,120.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748822 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748828 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748834 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748840 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748845 |
| Principal investigator 1 | Sequel Med Tech, LLC | $2,223.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748851 |
| Principal investigator 1 | Sequel Med Tech, LLC | $778.05 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748858 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748864 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748870 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748875 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748882 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748887 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748893 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748899 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748906 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748913 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748919 |
| Principal investigator 1 | Sequel Med Tech, LLC | $488.00 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748923 |
| Principal investigator 1 | Sequel Med Tech, LLC | $170.80 | 10/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243748927 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $11,384.80 | 10/30/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220791182 |
| Principal investigator 1 | Abbott Laboratories | $186.00 | 10/27/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136818 |
| Principal investigator 1 | Abbott Laboratories | $496.00 | 10/27/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136820 |
| Principal investigator 1 | Abbott Laboratories | $61.00 | 10/27/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136822 |
| Principal investigator 1 | Abbott Laboratories | $13.95 | 10/27/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136824 |
| Principal investigator 1 | Abbott Laboratories | $1.40 | 10/27/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136826 |
| Principal investigator 1 | Abbott Laboratories | $40.17 | 10/27/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136828 |
| Principal investigator 1 | Abbott Laboratories | $7.59 | 10/27/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136830 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 10/27/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619832 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.74 | 10/27/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619834 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.74 | 10/27/2025 | Non-covered Recipient Entity Iowa Diabetes | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220768901 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 10/27/2025 | Non-covered Recipient Entity Iowa Diabetes | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220768903 |
| Principal investigator 1 | Abbott Laboratories | $7.99 | 10/14/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136816 |
| Principal investigator 1 | Abbott Laboratories | $216.00 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136764 |
| Principal investigator 1 | Abbott Laboratories | $222.00 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136766 |
| Principal investigator 1 | Abbott Laboratories | $222.00 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136768 |
| Principal investigator 1 | Abbott Laboratories | $38.00 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136770 |
| Principal investigator 1 | Abbott Laboratories | $610.00 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136772 |
| Principal investigator 1 | Abbott Laboratories | $210.00 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136774 |
| Principal investigator 1 | Abbott Laboratories | $4.65 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136776 |
| Principal investigator 1 | Abbott Laboratories | $492.00 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136778 |
| Principal investigator 1 | Abbott Laboratories | $30.98 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136780 |
| Principal investigator 1 | Abbott Laboratories | $237.00 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136782 |
| Principal investigator 1 | Abbott Laboratories | $960.00 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136784 |
| Principal investigator 1 | Abbott Laboratories | $2,723.66 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136786 |
| Principal investigator 1 | Abbott Laboratories | $320.85 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136788 |
| Principal investigator 1 | Abbott Laboratories | $17.40 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136790 |
| Principal investigator 1 | Abbott Laboratories | $82.50 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136792 |
| Principal investigator 1 | Abbott Laboratories | $26.25 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136794 |
| Principal investigator 1 | Abbott Laboratories | $9.00 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136796 |
| Principal investigator 1 | Abbott Laboratories | $13.00 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136798 |
| Principal investigator 1 | Abbott Laboratories | $58.50 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136800 |
| Principal investigator 1 | Abbott Laboratories | $211.20 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136802 |
| Principal investigator 1 | Abbott Laboratories | $28.56 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136804 |
| Principal investigator 1 | Abbott Laboratories | $171.30 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136806 |
| Principal investigator 1 | Abbott Laboratories | $17.70 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136808 |
| Principal investigator 1 | Abbott Laboratories | $555.00 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136810 |
| Principal investigator 1 | Abbott Laboratories | $29,999.40 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136812 |
| Principal investigator 1 | Abbott Laboratories | $36.75 | 10/13/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136814 |
| Principal investigator 1 | ABBVIE INC. | $14,652.12 | 10/09/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202515975 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619796 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619798 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619800 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619802 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619804 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619806 |
| Principal investigator 1 | Sequel Med Tech, LLC | $3,200.00 | 09/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243746996 |
| Principal investigator 1 | Sequel Med Tech, LLC | $1,120.00 | 09/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243747002 |
| Principal investigator 1 | Sequel Med Tech, LLC | $3,200.00 | 09/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243747007 |
| Principal investigator 1 | Sequel Med Tech, LLC | $1,120.00 | 09/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243747014 |
| Principal investigator 1 | Sequel Med Tech, LLC | $3,200.00 | 09/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243747022 |
| Principal investigator 1 | Sequel Med Tech, LLC | $1,120.00 | 09/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243747028 |
| Principal investigator 1 | Sequel Med Tech, LLC | $3,200.00 | 09/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243747035 |
| Principal investigator 1 | Sequel Med Tech, LLC | $1,120.00 | 09/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243747041 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.96 | 09/24/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619786 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 09/24/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619788 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,022.00 | 09/24/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619790 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $442.20 | 09/24/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619792 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $27.84 | 09/24/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619794 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 09/23/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220791180 |
| Principal investigator 1 | Sequel Med Tech, LLC | $54.27 | 09/23/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243746612 |
| Principal investigator 1 | Novo Nordisk AS | $1,965.94 | 09/19/2025 | Non-covered Recipient Entity MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY | NN9535-4352 | No dispute reported | 06/30/2026 | 1213799344 |
| Principal investigator 1 | Sequel Med Tech, LLC | $20.00 | 09/19/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243746606 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,114.90 | 09/18/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220791178 |
| Principal investigator 1 | ABBVIE INC. | $26,124.84 | 09/04/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202509112 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619748 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619750 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619752 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619754 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619756 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619774 |
| Principal investigator 1 | Sequel Med Tech, LLC | $66.77 | 09/01/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243746596 |
| Principal investigator 1 | Sequel Med Tech, LLC | $3,200.00 | 08/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243745600 |
| Principal investigator 1 | Sequel Med Tech, LLC | $1,120.00 | 08/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243745607 |
| Principal investigator 1 | Sequel Med Tech, LLC | $3,200.00 | 08/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243745612 |
| Principal investigator 1 | Sequel Med Tech, LLC | $1,120.00 | 08/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243745617 |
| Principal investigator 1 | Sequel Med Tech, LLC | $3,200.00 | 08/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243745623 |
| Principal investigator 1 | Sequel Med Tech, LLC | $1,120.00 | 08/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243745630 |
| Principal investigator 1 | Eli Lilly and Company | $6,100.00 | 08/28/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187881272 |
| Principal investigator 1 | Novo Nordisk AS | $877.29 | 08/22/2025 | Non-covered Recipient Entity MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY | NN9535-4352 | No dispute reported | 06/30/2026 | 1213803664 |
| Principal investigator 1 | ABBVIE INC. | $36,811.88 | 08/06/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202502963 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $23,995.10 | 08/06/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220791176 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619738 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619740 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619742 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619744 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619746 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.79 | 08/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619768 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619772 |
| Principal investigator 1 | Sequel Med Tech, LLC | $8,000.00 | 07/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243745046 |
| Principal investigator 1 | Sequel Med Tech, LLC | $2,800.00 | 07/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243745050 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $104.94 | 07/28/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619776 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.74 | 07/28/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619778 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $438.00 | 07/28/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619780 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.22 | 07/28/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619782 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.88 | 07/28/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619784 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.00 | 07/28/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220791170 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $600.00 | 07/25/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220791168 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.00 | 07/25/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220791172 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $570.00 | 07/22/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220791174 |
| Principal investigator 1 | Abbott Laboratories | $740.00 | 07/21/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136762 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $95.00 | 07/19/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220791166 |
| Principal investigator 1 | Novo Nordisk AS | $1,180.69 | 07/18/2025 | Non-covered Recipient Entity MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY | NN9535-4352 | No dispute reported | 06/30/2026 | 1213819195 |
| Principal investigator 1 | Abbott Laboratories | $52.50 | 07/17/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136748 |
| Principal investigator 1 | Abbott Laboratories | $1,628.00 | 07/16/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136740 |
| Principal investigator 1 | Abbott Laboratories | $1,932.92 | 07/16/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136742 |
| Principal investigator 1 | Abbott Laboratories | $310.50 | 07/16/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136744 |
| Principal investigator 1 | Abbott Laboratories | $21,956.00 | 07/16/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136746 |
| Principal investigator 1 | Abbott Laboratories | $18.00 | 07/16/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136750 |
| Principal investigator 1 | Abbott Laboratories | $8.00 | 07/16/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136752 |
| Principal investigator 1 | Abbott Laboratories | $36.00 | 07/16/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136754 |
| Principal investigator 1 | Abbott Laboratories | $140.80 | 07/16/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136756 |
| Principal investigator 1 | Abbott Laboratories | $47.60 | 07/16/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136758 |
| Principal investigator 1 | Abbott Laboratories | $48.00 | 07/16/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136760 |
| Principal investigator 1 | ABBVIE INC. | $5,000.00 | 07/15/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202498270 |
| Principal investigator 1 | Dexcom, Inc. | $1,800.00 | 07/14/2025 | Non-covered Recipient Entity Iowa Diabetes & Endocrinology Research Center | Potential outcomes of continuous glucose monitors in low income patients with type 2 diabetes not on insulin therapy. | No dispute reported | 06/30/2026 | 1250961764 |
| Principal investigator 1 | Eli Lilly and Company | $3,500.00 | 07/14/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187881278 |
| Principal investigator 1 | ABBVIE INC. | $13,381.38 | 07/02/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202495721 |
| Principal investigator 1 | Novo Nordisk AS | $2,000.00 | 07/02/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH CENTER | NN9535-4801 | No dispute reported | 06/30/2026 | 1213743709 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619758 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619760 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619762 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619764 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619766 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619770 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,221.30 | 06/25/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220791164 |
| Principal investigator 1 | Novo Nordisk AS | $1,000.00 | 06/25/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH CENTER | NN9535-4801 | No dispute reported | 06/30/2026 | 1213723167 |
| Principal investigator 1 | Novo Nordisk AS | $2,504.00 | 06/25/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH CENTER | NN9535-4801 | No dispute reported | 06/30/2026 | 1213728376 |
| Principal investigator 1 | Novo Nordisk AS | $386.44 | 06/25/2025 | Non-covered Recipient Entity MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY | NN9535-4352 | No dispute reported | 06/30/2026 | 1213760726 |
| Principal investigator 1 | Medtronic, Inc. | $5,150.00 | 06/17/2025 | Non-covered Recipient Entity Iowa Diabetes And Endocrinology Research Center Plc. | CIP341 IMPACT2 | No dispute reported | 06/30/2026 | 1192323149 |
| Principal investigator 1 | ABBVIE INC. | $44,183.50 | 06/03/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202489203 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619720 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619722 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619724 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619726 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619728 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619730 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.98 | 05/27/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619732 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 05/27/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619734 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.48 | 05/27/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619736 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $5,350.00 | 05/26/2025 | Non-covered Recipient Entity IOWA DIABETES & ENDOCRINOLOGY RESEARCH | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248244505 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $500.00 | 05/26/2025 | Non-covered Recipient Entity IOWA DIABETES & ENDOCRINOLOGY RESEARCH | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248244509 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,000.00 | 05/26/2025 | Non-covered Recipient Entity IOWA DIABETES & ENDOCRINOLOGY RESEARCH | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248244513 |
| Principal investigator 1 | Medtronic, Inc. | $300.00 | 05/23/2025 | Non-covered Recipient Entity Iowa Diabetes And Endocrinology Research Center Plc. | CIP341 IMPACT2 | No dispute reported | 06/30/2026 | 1192323147 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,699.60 | 05/09/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220791162 |
| Principal investigator 1 | ABBVIE INC. | $21,018.43 | 05/07/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202484121 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619708 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619710 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619712 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619714 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619716 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619718 |
| Principal investigator 1 | Sequel Med Tech, LLC | $4,000.00 | 04/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243743421 |
| Principal investigator 1 | Sequel Med Tech, LLC | $1,400.00 | 04/30/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC | Innovative Automated Insulin Delivery System for T2D | No dispute reported | 06/30/2026 | 1243743427 |
| Principal investigator 1 | Abbott Laboratories | $1,420.80 | 04/24/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136718 |
| Principal investigator 1 | Abbott Laboratories | $1,757.20 | 04/24/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136720 |
| Principal investigator 1 | Abbott Laboratories | $310.50 | 04/24/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136722 |
| Principal investigator 1 | Abbott Laboratories | $19,960.00 | 04/24/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136724 |
| Principal investigator 1 | Abbott Laboratories | $52.50 | 04/24/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136726 |
| Principal investigator 1 | Abbott Laboratories | $18.00 | 04/24/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136728 |
| Principal investigator 1 | Abbott Laboratories | $8.00 | 04/24/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136730 |
| Principal investigator 1 | Abbott Laboratories | $36.00 | 04/24/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136732 |
| Principal investigator 1 | Abbott Laboratories | $140.80 | 04/24/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136734 |
| Principal investigator 1 | Abbott Laboratories | $47.60 | 04/24/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136736 |
| Principal investigator 1 | Abbott Laboratories | $64.80 | 04/24/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136738 |
| Principal investigator 1 | Novo Nordisk AS | $166.00 | 04/23/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RESEARCH CENTER | NN9535-4801 | No dispute reported | 06/30/2026 | 1213737147 |
| Principal investigator 1 | Novo Nordisk AS | $511.76 | 04/21/2025 | Non-covered Recipient Entity MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY | NN9535-4352 | No dispute reported | 06/30/2026 | 1213741967 |
| Principal investigator 1 | Novo Nordisk AS | $1,580.63 | 04/21/2025 | Non-covered Recipient Entity MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY | NN9535-4352 | No dispute reported | 06/30/2026 | 1213838946 |
| Principal investigator 1 | Eli Lilly and Company | $10,843.00 | 04/15/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187882782 |
| Principal investigator 1 | Eli Lilly and Company | $425.00 | 04/14/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | No dispute reported | 06/30/2026 | 1187882544 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,858.90 | 04/11/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220791160 |
| Principal investigator 1 | Dexcom, Inc. | $10,000.00 | 04/08/2025 | Non-covered Recipient Entity Iowa Diabetes & Endocrinology Research Center | Potential outcomes of continuous glucose monitors in low income patients with type 2 diabetes not on insulin therapy. | No dispute reported | 06/30/2026 | 1250961760 |
| Principal investigator 1 | Eli Lilly and Company | $6,650.00 | 04/07/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A PHASE 3B, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED TO SEMAGLUTIDE 2.4 MG IN ADULTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (SURMOUNT-5) | No dispute reported | 06/30/2026 | 1187882542 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619696 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619698 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619700 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619702 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619704 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619706 |
| Principal investigator 1 | Novo Nordisk AS | $23,550.70 | 03/31/2025 | Non-covered Recipient Entity MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY | EX9924-4473 | No dispute reported | 06/30/2026 | 1213764496 |
| Principal investigator 1 | Eli Lilly and Company | $6,950.00 | 03/28/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | No dispute reported | 06/30/2026 | 1187884986 |
| Principal investigator 1 | Novo Nordisk AS | $4,000.00 | 03/28/2025 | Non-covered Recipient Entity MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY | EX9924-4473 | No dispute reported | 06/30/2026 | 1213800466 |
| Principal investigator 1 | Abbott Laboratories | $1,458.90 | 03/27/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System | No dispute reported | 06/30/2026 | 1248136708 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $32,971.65 | 03/24/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220791158 |
| Principal investigator 1 | Eli Lilly and Company | $113.20 | 03/17/2025 | Covered Recipient Teaching Hospital CHILDRENS HOSPITAL MEDICAL CENTER | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187871797 |
| Principal investigator 1 | ABBVIE INC. | $18,422.03 | 03/07/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202461353 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619676 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619678 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619680 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619682 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619684 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619686 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $663.30 | 02/25/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619692 |
| Principal investigator 1 | Dexcom, Inc. | $3,400.00 | 02/25/2025 | Non-covered Recipient Entity Iowa Diabetes & Endocrinology Research Center | MULTI-SESSION FEASIBILITY STUDY OF THE DEXCOM G7 DELTA CONTINUOUS GLUCOSE MONITORING (CGM) SENSOR IN ADULT AND PEDIATRIC SUBJECTS | No dispute reported | 06/30/2026 | 1250961766 |
| Principal investigator 1 | Novo Nordisk AS | $2,000.00 | 02/21/2025 | Non-covered Recipient Entity MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY | EX9924-4473 | No dispute reported | 06/30/2026 | 1213780534 |
| Principal investigator 1 | Novo Nordisk AS | $807.75 | 02/21/2025 | Non-covered Recipient Entity MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY | NN9535-4352 | No dispute reported | 06/30/2026 | 1213792643 |
| Principal investigator 1 | Novo Nordisk AS | $511.76 | 02/21/2025 | Non-covered Recipient Entity MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY | NN9535-4352 | No dispute reported | 06/30/2026 | 1213824064 |
| Principal investigator 1 | Eli Lilly and Company | $763.46 | 02/17/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES | No dispute reported | 06/30/2026 | 1187881274 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,076.35 | 02/13/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220791156 |
| Principal investigator 1 | Eli Lilly and Company | $102,219.00 | 02/11/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | No dispute reported | 06/30/2026 | 1187884766 |
| Principal investigator 1 | Dexcom, Inc. | $3,400.00 | 02/04/2025 | Non-covered Recipient Entity Iowa Diabetes & Endocrinology Research Center | MULTI-SESSION FEASIBILITY STUDY OF THE DEXCOM G7 DELTA CONTINUOUS GLUCOSE MONITORING (CGM) SENSOR IN ADULT AND PEDIATRIC SUBJECTS | No dispute reported | 06/30/2026 | 1250961768 |
| Principal investigator 1 | Eli Lilly and Company | $47,204.00 | 02/04/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, TWO-ARM, PHASE 4 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED WITH INTENSIFIED CONVENTIONAL CARE IN ADULTS WHEN INITIATING TREATMENT EARLY IN THE COURSE OF TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187885180 |
| Principal investigator 1 | Eli Lilly and Company | $200.00 | 02/03/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) | No dispute reported | 06/30/2026 | 1187883936 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619664 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619666 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619668 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619670 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619672 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619674 |
| Principal investigator 1 | Eli Lilly and Company | $379.56 | 01/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | No dispute reported | 06/30/2026 | 1187882546 |
| Principal investigator 1 | Eli Lilly and Company | $799.60 | 01/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | No dispute reported | 06/30/2026 | 1187885182 |
| Principal investigator 1 | Eli Lilly and Company | $4,278.32 | 01/31/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187885184 |
| Principal investigator 1 | Medtronic, Inc. | $958.00 | 01/31/2025 | Non-covered Recipient Entity Iowa Diabetes And Endocrinology Research Center Plc. | CIP341 IMPACT2 | No dispute reported | 06/30/2026 | 1192323145 |
| Principal investigator 1 | Novo Nordisk AS | $1,177.33 | 01/31/2025 | Non-covered Recipient Entity MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY | NN9535-4352 | No dispute reported | 06/30/2026 | 1213736329 |
| Principal investigator 1 | Eli Lilly and Company | $7,692.49 | 01/28/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187883128 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.24 | 01/27/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619688 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.16 | 01/27/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619690 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17,023.05 | 01/27/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220791154 |
| Principal investigator 1 | Eli Lilly and Company | $85,449.00 | 01/27/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187883134 |
| Principal investigator 1 | Eli Lilly and Company | $940.90 | 01/27/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187884034 |
| Principal investigator 1 | Eli Lilly and Company | $5,600.00 | 01/27/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A STUDY OF TIRZEPATIDE (LY3298176) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES SWITCHING FROM DULAGLUTIDE (SURPASS-SWITCH) (SURPASS-SWITCH) | No dispute reported | 06/30/2026 | 1187884768 |
| Principal investigator 1 | Eli Lilly and Company | $1,612.18 | 01/27/2025 | Non-covered Recipient Entity PRAIRIE EDUCATION AND RESEARCH COOP | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187887526 |
| Principal investigator 1 | Dexcom, Inc. | $615.00 | 01/23/2025 | Non-covered Recipient Entity Iowa Diabetes & Endocrinology Research Center | Potential outcomes of continuous glucose monitors in low income patients with type 2 diabetes not on insulin therapy. | No dispute reported | 06/30/2026 | 1250961762 |
| Principal investigator 1 | Eli Lilly and Company | $1,668.18 | 01/22/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187884770 |
| Principal investigator 1 | Eli Lilly and Company | $48,513.00 | 01/21/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187881264 |
| Principal investigator 1 | Eli Lilly and Company | $792.63 | 01/21/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187882450 |
| Principal investigator 1 | Eli Lilly and Company | $38,426.00 | 01/21/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187883132 |
| Principal investigator 1 | Eli Lilly and Company | $229,853.00 | 01/21/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187884984 |
| Principal investigator 1 | Eli Lilly and Company | $79,589.00 | 01/21/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187885178 |
| Principal investigator 1 | Abbott Laboratories | $10.56 | 01/20/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136710 |
| Principal investigator 1 | Abbott Laboratories | $17.68 | 01/20/2025 | Non-covered Recipient Entity Iowa Diabetes & Endo Research Center | ISM2305001A--CGM Comparison Study | No dispute reported | 06/30/2026 | 1248136712 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $11,770.50 | 01/17/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220791146 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.00 | 01/10/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220791148 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $228.00 | 01/10/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220791150 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8.00 | 01/10/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220791152 |
| Principal investigator 1 | Eli Lilly and Company | $6,676.26 | 01/09/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187881270 |
| Principal investigator 1 | Eli Lilly and Company | $878.19 | 01/09/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187883938 |
| Principal investigator 1 | Dexcom, Inc. | $9,899.00 | 01/07/2025 | Non-covered Recipient Entity Iowa Diabetes & Endocrinology Research Center | EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM PROTOCOL | No dispute reported | 06/30/2026 | 1250961770 |
| Principal investigator 1 | Eli Lilly and Company | $75,157.00 | 01/07/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187881266 |
| Principal investigator 1 | Eli Lilly and Company | $45,112.00 | 01/07/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | No dispute reported | 06/30/2026 | 1187881268 |
| Principal investigator 1 | Eli Lilly and Company | $373,768.00 | 01/07/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES | No dispute reported | 06/30/2026 | 1187882540 |
| Principal investigator 1 | Eli Lilly and Company | $49,500.00 | 01/07/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187884988 |
| Principal investigator 1 | Eli Lilly and Company | $9.30 | 01/03/2025 | Non-covered Recipient Entity IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR | A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, TWO-ARM, PHASE 4 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED WITH INTENSIFIED CONVENTIONAL CARE IN ADULTS WHEN INITIATING TREATMENT EARLY IN THE COURSE OF TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187882448 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619654 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619656 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619658 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619660 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619662 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Mercyone Des Moines Diabetes And Endocrinology Care | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220619694 |